Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level

Modern Rheumatology

Volumn 19, Issue 5, 2009, Pages 507-512

  Funahashi, Keiko ^a   Koyano, Satoru ^b   Miura, Takako ^a   Hagiwara, Takafumi ^a   Okuda, Kosuke ^a   Matsubara, Tsukasa ^a,b  

^a Matsubara Mayflower Hospital   (Japan)

^b Research Institute of Joint Diseases   (Japan)

Author keywords

Clinical disease activity index; DAS28; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ATLIZUMAB; BIOLOGICAL MARKER; INTERLEUKIN 6; STROMELYSIN;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY SCORE 28; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70350028295     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0203-z     Document Type: Article

References (22)

1. Nishihimoto N, Hashimoto J, Miyasaka N, Yamamotro K, Kawai S, Kishimoto T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-7.
2. Nishimoto N, Terao K, Nakahara H, Takagi N, Kakehi T. Mechanism and pathologic significances in increase in serum interleukin-6(IL-6) and soluble Il-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959-64.
3. Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Smolen JS, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res Ther. 2005;7:796-806.
4. Alethaha D, Smolen JS. The simple disease activity index (SDAI) and the clinical disease activity index (CDAI). A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(Suppl 39):S100-8.
5. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2004;50:1761-9.
6. Smolen SJ, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomized trial. Lancet. 2008;371:987-97.
7. Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Yamanaka H, et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol. 2007;17:403-8.
8. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH. Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21:465-72.
9. Posthumus MD, Limburg PC, Westra J, Leeuwen MA, Rijswijk MH. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol. 2000;27:2761-8.
10. Ribbens C, Andre B, Jaspar JM, Kaya O, Kaiser MJ, Malaise MG, et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol. 2000;27:888-93.
11. Sugiyama E. Clinical usefulness of serum levels of MMP-3 and IL-6 in rheumatoid arthritis. Ryumachiika. 1998;20:575-80.
12. Shaver TS, Anderson JD, Weidensaul DN, Shahouri SS, Busch RE, Wolfe E, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol. 2008;35:1015-22.
13. Sokka T, Hetland ML, Makinen H, Kautiainen H, Horslev-Petersen K, Pincus T, et al. Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008;58:2642-51.
14. Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity of RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology. 2000;39:321-7.
15. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rinthelen B. Patients-centered rheumatoid arthritis disease activity assessment by modified RADAI. J Rheumatol. 2008;35:1294-9.
16. Stucki G, Liang MH, Stucki S, Bruhlmann P, Michl B. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Arthritis Rheum. 1995;38:795-8.
17. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observation studies, and clinical trials: The patient activity scale (PAS/PAS-II). J Rheumatol. 2005;32:2410-5.
18. Pincus T, Swearingen C, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patients Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008;35:2136-47.
19. Hussiau FK, Devogelaer JP, Van Damme J, de Dexchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31:784-8.
20. Madhok R, Crilly A, Watoson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: Correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232-4.
21. Ribbens C, Andre B, Kaya O, Kaiser MJ, Bonnet V, Malaise MG. Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not. Rheumatology. 2000;39:1357-65.
22. Klimiuk PA, Sierakowski S, Chwie KJ. Serum interleukin 6 concentration correlates with matrix metalloproteinase and their tissue inhibitors in rheumatoid arthritis. Pol Arch Med Wewn. 2003;109:119-23.